Multiple Sclerosis - Pipeline Review, H2 Pharmaceutical 2016
Albany, New York, Jan 20,2017
"Multiple
Sclerosis - Pipeline Review, H2 2016"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Multiple Sclerosis Pipeline Review, H2 2016, provides
an overview of the Multiple Sclerosis (Central Nervous System)
pipeline landscape.
Multiple
sclerosis (MS) is a potentially debilitating disease in which body's
immune system eats away at the protective sheath (myelin) that covers
nerves. Damage to myelin causes interference in the communication
between brain, spinal cord and other areas of body. Symptoms include
numbness or weakness in one or more limbs, double vision or blurring
of vision, tingling or pain in parts of body, fatigue and slurred
speech. The predisposing factors include age, gender, family history
and certain infections.
*
Report Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Multiple Sclerosis Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Multiple
Sclerosis (Central Nervous System), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Multiple Sclerosis (Central Nervous System) pipeline guide also
reviews of key players involved in therapeutic development for
Multiple Sclerosis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I, Preclinical,
Discovery and Unknown stages are 5, 9, 30, 32, 173, 36 and 2
respectively. Similarly, the Universities portfolio in Phase II,
Phase I, Preclinical and Discovery stages comprises 1, 4, 46 and 2
molecules, respectively.
Multiple
Sclerosis (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide
is built using data and information sourced from Global Markets
Directs proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
*
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Multiple Sclerosis (Central Nervous System).
-
The pipeline guide reviews pipeline therapeutics for Multiple
Sclerosis (Central Nervous System) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Multiple
Sclerosis (Central Nervous System) therapeutics and enlists all their
major and minor projects.
-
The pipeline guide evaluates Multiple Sclerosis (Central Nervous
System) therapeutics based on mechanism of action (MoA), drug target,
route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Multiple Sclerosis (Central Nervous System)
*
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Multiple Sclerosis (Central Nervous System).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Multiple Sclerosis (Central Nervous System) pipeline depth and focus
of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Comments
Post a Comment